Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-26, Stock:ABBV, The news for the past five days is as follows:
2018-04-19: NEWS1: Mylan NV Could Be Closer to a Breakout Than Most Traders Realize.NEWS2: Gilead Sciences Expects Decline in Earnings in Fiscal 2018.NEWS3: Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising.NEWS4: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.NEWS5: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.
2018-04-20: NEWS1: J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?.NEWS2: J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?.NEWS3: AbbVie And Other Great Pharma And Biotech Income Stocks.
2018-04-23: NEWS1: Is a Beat in Store for Alexion (ALXN) This Earnings Season?.NEWS2: Is a Beat in Store for Alexion (ALXN) This Earnings Season?.NEWS3: What Lies Ahead for Vice ETFs?.NEWS4: What Lies Ahead for Vice ETFs?.NEWS5: Johnson & Johnson’s Revenues Continued to Rise in 1Q18.NEWS6: Amid drug price worries, earnings to test U.S. pharma, biotech shares.NEWS7: Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy.NEWS8: Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy.NEWS9: Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?.NEWS10: Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?.NEWS11: Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?.NEWS12: Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?.NEWS13: Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy.NEWS14: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS15: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS16: Implied DIVB Analyst Target Price: $29.NEWS17: Implied DIVB Analyst Target Price: $29.
2018-04-24: NEWS1: U.S. Supreme Court upholds legality of patent review process.NEWS2: Gilead Sciences Focuses on Its Liver Disease Portfolio.NEWS3: Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down.NEWS4: Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down.NEWS5: Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?.NEWS6: Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?.NEWS7: Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?.NEWS8: Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down.NEWS9: How Does Biogen Make its Money?.NEWS10: U.S. Supreme Court upholds legality of patent review process.NEWS11: What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?.NEWS12: What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?.NEWS13: U.S. Supreme Court upholds legality of patent review process.NEWS14: Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma.NEWS15: Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma.NEWS16: This Small Biotech Is Building on a Surprising Success.NEWS17: Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?.NEWS18: Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?.NEWS19: Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma.NEWS20: Amid drug price worries, earnings to test U.S. pharma, biotech shares.NEWS21: Modern Miracles: America's 10 Best-Selling Drugs.NEWS22: Modern Miracles: America's 10 Best-Selling Drugs.
2018-04-25: NEWS1: Pre-Market Earnings Report for April 26, 2018 :  ABBV, PEP, MO, UNP, BMY, COP, TWX, UPS, RTN, CME, GM, ITW.NEWS2: Pre-Market Earnings Report for April 26, 2018 :  ABBV, PEP, MO, UNP, BMY, COP, TWX, UPS, RTN, CME, GM, ITW.NEWS3: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS4: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS5: What's in the Cards for Inogen (INGN) This Earnings Season?.NEWS6: What's in the Cards for Inogen (INGN) This Earnings Season?.NEWS7: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS8: Shire willing to back $64 billion Takeda bid, market signals doubts.NEWS9: AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis.NEWS10: A Look at Biogen’s Performance in 1Q18.NEWS11: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients.NEWS12: Why Incyte Stock Fell ~9% on April 24.NEWS13: Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress.NEWS14: Supreme Court upholds legality of patent review process.

Answer: Rise